Abstract
Chronic lower back pain caused by intervertebral disc degeneration and osteoarthritis (OA) are highly prevalent chronic diseases. Although pain management and surgery can alleviate symptoms, no disease-modifying treatments are available. mRNA delivery could halt inflammation and degeneration and induce regeneration by overexpressing anti-inflammatory cytokines or growth factors involved in cartilage regeneration. Here, we investigated poly(amidoamine)-based polymeric nanoparticles to deliver mRNA to human joint and intervertebral disc cells. Human OA chondrocytes, human nucleus pulposus (NP) cells, human annulus fibrosus (AF) cells, fibroblast-like synoviocytes (FLS) and M1-like macrophages were cultured and transfected with uncoated or PGA-PEG-coated nanoparticles loaded with EGFP-encoding mRNA. Cell viability and transfection efficiency were analyzed for all cell types. Nanoparticle internalization was investigated in FLS and M1-like macrophages. No significant decrease in cell viability was observed in most conditions. Only macrophages showed a dose-dependent reduction of viability. Transfection with either nanoparticle version resulted in EGFP expression in NP cells, AF cells, OA chondrocytes and FLS. Macrophages showed internalization of nanoparticles by particle-cell co-localization, but no detectable expression of EGFP. Taken together, our data show that poly (amidoamine)-based nanoparticles can be used for mRNA delivery into cells of the human joint and intervertebral disc, indicating its potential future use as an mRNA delivery system in OA and IVDD, except for macrophages.
Original language | English |
---|---|
Article number | 438 |
Number of pages | 15 |
Journal | Pharmaceutics |
Volume | 16 |
Issue number | 4 |
DOIs | |
Publication status | Published - 22 Mar 2024 |
Bibliographical note
Publisher Copyright:© 2024 by the authors.
Funding
This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 955335 and grant agreement No. 825925 and the Dutch Arthritis Foundation under grant number LLP12 and grant number LLP14.
Funders | Funder number |
---|---|
Horizon 2020 Framework Programme | |
H2020 Marie Skłodowska-Curie Actions | 825925, 955335 |
H2020 Marie Skłodowska-Curie Actions | |
Dutch Arthritis Association | LLP14 |
Dutch Arthritis Association |
Keywords
- chronic lower back pain
- mRNA delivery
- nanomedicine
- osteoarthritis